Novartis AG ADR (NVS)vsUFP Technologies Inc (UFPT)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
UFPT
UFP Technologies Inc
$185.45
-5.02%
HEALTHCARE · Cap: $1.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 9286% more annual revenue ($56.58B vs $602.80M). NVS leads profitability with a 23.9% profit margin vs 11.3%. NVS appears more attractively valued with a PEG of 2.48. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
UFPT
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
-89.1%
Fair Value
$139.28
Current Price
$185.45
$46.17 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
3.4% revenue growth
Smaller company, higher risk/reward
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : UFPT
UFPT has a balanced fundamental profile.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : UFPT
The primary concerns for UFPT are Revenue Growth, Market Cap, PEG Ratio.
Key Dynamics to Monitor
NVS profiles as a declining stock while UFPT is a value play — different risk/reward profiles.
UFPT carries more volatility with a beta of 1.17 — expect wider price swings.
UFPT is growing revenue faster at 3.4% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 49/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →UFP Technologies Inc
HEALTHCARE · MEDICAL DEVICES · USA
UFP Technologies, Inc. designs and converts foams, films and plastic materials for the medical, automotive, consumer, electronic, industrial, aerospace and defense markets in the United States. The company is headquartered in Newburyport, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?